Patents by Inventor James E. Hagstrom

James E. Hagstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reversibly masked polymers
    Patent number: 10022456
    Abstract: The present invention is directed to reversibly inactivated membrane active polymers useful for cellular delivery of compounds. Described are polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 17, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David B Rozema, Jon A Wolff, James E Hagstrom, Kirk Ekena
  • Reversibly Masked Polymers
    Publication number: 20150273081
    Abstract: The present invention is directed to reversibly inactivated membrane active polymers useful for cellular delivery of compounds. Described are polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: January 12, 2015
    Publication date: October 1, 2015
    Inventors: David B Rozema, Jon A Wolff, James E Hagstrom, Kirk Ekena
  • Polyconjugates for in vivo delivery of polynucleotides
    Patent number: 8658211
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: February 25, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jason Klein, So Wong, Jon A. Wolff, James E. Hagstrom
  • Polyconjugates for In Vivo Delivery of Polynucleotides
    Publication number: 20120230938
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: February 8, 2012
    Publication date: September 13, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. ROZEMA, Darren H. WAKEFIELD, David L. LEWIS, Jason KLEIN, So WONG, Jon A. WOLFF, James E. HAGSTROM
  • Endosomolytic polymers
    Patent number: 8211468
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: July 3, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom, Kirk Ekena
  • Polyconjugates for in vivo delivery of polynucleotides
    Patent number: 8137695
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, James E. Hagstrom, Jason Klein, David L. Lewis, Sean D. Monahan, Darren H. Wakefield, Jon A. Wolff, So Wong
  • Membrane active heteropolymers
    Patent number: 8138383
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Method for single-step attachment of a label to target molecules
    Patent number: 8129509
    Abstract: Compounds and methods are provided for a single-step covalent attachment of a label to a molecule comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeling reagent with a mixture containing the molecule, under conditions wherein the labeling reagent has reactivity with the molecule thereby forming a covalent bond.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: March 6, 2012
    Assignee: Mirus Bio LLC
    Inventors: Paul M. Slattum, Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker
  • Endosomolytic poly(acrylate) polymers
    Patent number: 8017109
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 13, 2011
    Assignee: Roche Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Endosomolytic poly(vinyl ether) polymers
    Patent number: 8008355
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Membrane active heteropolymers
    Patent number: 7985406
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: July 26, 2011
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Reversible attachment of a membrane active polymer to a polynucleotide
    Patent number: 7816337
    Abstract: Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 19, 2010
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren Wakefield, Jon A Wolff, Kirk Ekena, James E. Hagstrom
  • Intravenous delivery of polynucleotides to cells in mammalian limb
    Patent number: 7803782
    Abstract: An intravenous delivery method is described that enables delivery of polynucleotides to extravascular cells of a mammalian limb. The method involves the injection of polynucleotides into a distal vein of a limb that is transiently occluded. Polynucleotide delivery is facilitated by rapid injection in sufficient volume to enable extravasation of the solution into surrounding tissue.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: September 28, 2010
    Assignee: Roche Madison Inc.
    Inventors: James E. Hagstrom, Julia Hegge, Hans Herweijer, Jon A. Wolff
  • Compositions and processes using siRNA, amphipathic compounds and polycations
    Patent number: 7601367
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 13, 2009
    Assignee: Mirus Bio LLC
    Inventors: Sean D. Monahan, David L. Lewis, Hans Herweijer, Jon A. Wolff, James E. Hagstrom, Aaron G. Loomis, Vladimir Trubetskoy, Lori Higgs
  • Delivery of molecules and complexes to mammalian cells in vivo
    Patent number: 7589059
    Abstract: Disclosed is a system for providing in vivo delivery of molecules or complexes to extravascular mammalian cells using an intravascular administration route. The molecules or complexes are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate transiently increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the molecule to the cell.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: September 15, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, Vladimir G. Budker, Hans Herweijer, James E. Hagstrom, Sean D. Monahan, Julia Hegge, Vladimir Subbotin
  • Nucleic acid injected into hepatic vein lumen
    Patent number: 7547683
    Abstract: Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: June 16, 2009
    Assignee: Roche Madison, Inc.
    Inventors: Jon A. Wolff, Tatyana Budker, legal representative, Julia Hegge, James E. Hagstrom, Vladimir G. Budker
  • Polyampholytes for delivering polyions to a cell
    Patent number: 7524680
    Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 28, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker, Vladimir S. Trubetskoy
  • Membrane Active Heteropolymers
    Publication number: 20090048410
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: February 19, 2009
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Gene expression with covalently modified polynucleotides
    Patent number: 7491538
    Abstract: A process and compound wherein nucleic acids can be modified with a host of molecules and maintain their ability to be expressed. A modifying chemical attachment of polyions to polynucleotides can be used to facilitate the change of tertiary structure of the nucleic acid and in some cases condensation of nucleic acids into smaller, charged particles useful in delivering the nucleic acid to a cell.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: February 17, 2009
    Assignee: Mirus Bio LLC
    Inventors: Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Paul M. Slattum
  • Process of making a compound by forming a polymer from a template drug
    Patent number: 7482160
    Abstract: A method of forming polymers in the presence of nucleic acid using template polymerization. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 27, 2009
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, David B. Rozema, Vladimir Trubetskoy, Paul M. Slattum, Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Lisa J. Hanson